Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

With a team of dedicated specialists, the New Mexico Cancer Center uses the latest technology, from blood tests and imaging ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

Eric Morrow told his doctor about his family history of prostate cancer and asked if he needed testing. His doctor said no.

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...

Former President Joe Biden's health reports from 2021–2024 showed no signs of prostate cancer before the former president's ...